Flucinar gel 0.25mg/g 15g №1

Name:
Flucinar gel for nar.prim. 0.25 mg/g in tubes 15 g in pack No. 1
Description:
Transparent colorless jelly-like mass with slight opalescence and a slight smell of ethanol. The main active substance Fluocinolone acetonide Product formGel Dosage 0.25 mg/g Pharmacological properties Fluocinolone acetonide is a highly active synthetic glucocorticosteroid for topical use. The drug has a strong anti-inflammatory, antipruritic and vasoconstrictive effect. Indications for use Flucinar in the form of a gel is indicated for short-term local treatment (in the first phase of treatment before prescribing the drug in the form of an ointment) of acute and severe uninfected inflammatory skin diseases that occur without exudation, accompanied by persistent itching or hyperkeratosis, responsive to treatment with glucocorticosteroids, such as: seborrheic dermatitis, urticaria, atopic dermatitis, allergic contact eczema, erythema multiforme, lupus erythematosus, long-term psoriasis, scalp psoriasis, lichen planus. The gel form allows you to apply the drug in a smaller amount on a larger surface of the skin compared to the ointment, therefore, reduce the dose of the drug, and also apply to the skin covered with hair. Flucinar gel can also be used in patients who are intolerant to ointments. Method of administration and doses At the beginning of treatment, the gel is used 2-3 times a day, and then, after mitigation of the acute inflammatory condition, no more than 1-2 times a day. Treatment should not be carried out without interruption for more than 2 weeks. Do not use on the face for more than 1 week. Within one week, you can apply no more than 1 tube of gel. The gel should be applied in a thin layer on the affected skin surface. If you need a deeper penetration of the drug, the gel can be rubbed into the skin at the site of application. Do not use occlusive dressings. If bandaging is necessary, an air-permeable bandage should be used. In children over 2 years of age, use with extreme caution only if necessary, once a day, on a small surface of the skin. Do not apply on the face. Use during pregnancy and lactation Flucinar can be used in women during pregnancy only when the benefit outweighs the risk of use. Absolutely contraindicated in the first trimester of pregnancy. It is not known to what extent fluocinolone acetonide is excreted in breast milk when applied topically. After the use of corticosteroids inside, no significant amount of hormones was found in breast milk that could affect the newborn. However, even if there is a benefit to the mother, it is better to stop using the drug, since the likelihood of adverse reactions in the infant is high. If you are pregnant or breastfeeding, you should consult your doctor before taking this medicine. Precautions If the drug causes symptoms of irritation or allergic skin reactions (skin itching, burning or redness), its use should be stopped immediately. Do not use the drug continuously for more than 2 weeks. With prolonged use on large areas of the skin, the incidence of adverse reactions increases, the likelihood of developing edema, hypertension, hyperglycemia, and decreased immunity. Since corticosteroids can be absorbed through the skin, long-term treatment, use on large skin surfaces, under occlusive dressing and in children should be avoided. Because children have a higher surface-to-body weight ratio than adults, they are at higher risk for systemic side effects of glucocorticosteroids, including hypothalamic-pituitary-adrenal axis dysfunction and Cushing’s syndrome. Corticosteroid therapy can have side effects on the growth and development of children. Periodic monitoring of the function of the adrenal cortex is shown by determining cortisol in the blood and in the urine after stimulation of the adrenal glands with ACTH. In case of infection at the site of application of the ointment, the doctor may prescribe additional antibacterial or antifungal treatment. If the symptoms of the infection persist, it is recommended to interrupt the use of the drug Flucinar for the period of treatment of the infection. Do not use the drug in the areas around the eyes, due to the risk of glaucoma or cataracts. On the skin of the face, axillary and inguinal region, the drug can be used only in case of special need, since its absorption increases and the risk of developing adverse reactions (telangiectasia, perioral dermatitis) increases even after a short use. The drug should not be applied to areas of atrophied skin. Caution should be exercised in the presence of subcutaneous tissue atrophy, especially in elderly patients. Avoid getting the drug in the eyes, open wounds and mucous membranes. If the drug gets into the eyes or mucous membranes, it is recommended to rinse them with plenty of water. As in the case of the use of systemic glucocorticosteroids, after external use of the drug, cataracts and glaucoma or such a rare disease as central serous chorioretinopathy (CSC) may develop. Consult your doctor if you experience blurred vision or other visual disturbances. It should be used with extreme caution in patients with psoriasis, since topical use of glucocorticosteroids can be dangerous due to the likelihood of recurrence of the disease after the development of tolerance, the risk of generalized pustular psoriasis and local systemic toxicity due to a decrease in the barrier function of the skin. The drug should be used in the smallest amount for the shortest possible time necessary to achieve a therapeutic effect. It is necessary to stop treatment gradually, increasing the intervals between applications. This medicinal product contains propylene glycol, which may cause skin irritation. Perhaps the development of allergic reactions (including delayed type) due to the presence of parahydroxybenzoates. Interaction with other drugs There is no information about any types of interaction with topical application of glucocorticoids. However, it should be borne in mind that patients using them should not be vaccinated against chickenpox and other vaccinations, especially if the drug is regularly applied to large areas of the skin, since a decrease in the immune response in the form of an insufficient amount of antibodies is possible. Flucinar may enhance the effect of immunosuppressive agents and weaken the effect of immunostimulants. Tell your doctor if you are currently or have recently taken other medicines. Contraindications for hypersensitivity to fluocinolone acetonide and other glucocorticosteroids or to any excipient; with bacterial, viral and fungal skin infections; with acne vulgaris and rosacea; with perioral dermatitis (dermatitis perioralis); after vaccination; in children under 2 years of age; with perianal and genital itching; with diaper dermatitis. Active ingredient: fluocinolone acetonide 0.25 mg/g Excipients: propylene glycol, citric acid monohydrate, ethanol 96%, disodium edetate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, carbomer 980, triethanolamine, purified water. Overdose After prolonged use on a large surface of the skin, overdose symptoms may occur, manifested in the form of increased side effects: edema, arterial hypertension, hyperglycemia, decreased immunity, and in severe cases, the development of Cushing’s disease. In this case, the drug should be gradually discontinued or weaker glucocorticosteroids should be used. Side effectsSkin and subcutaneous tissues Acne-like lesions, steroid purpura, stunted growth of epithelial cells, burning sensation, itching, irritation, severe atrophy of the subcutaneous tissue, dry skin, excessive hair growth or alopecia, discoloration of the skin or discoloration, skin atrophy and the formation of striae , telangiectasia, perioral dermatitis, folliculitis and secondary infections. Sometimes urticaria or macular-papular rash may appear, exacerbation of existing pathological changes. Eye disorders When applied topically to the skin of the eyelids, glaucoma or cataracts may develop. Due to the penetration of fluocinolone acetonide through the skin, undesirable systemic effects may develop, especially with prolonged use, application to large areas of the skin, the use of hermetic dressings and use in children. Blurred vision is sometimes observed – the frequency of development is unknown. Systemic effects Undesirable systemic effects characteristic of fluocinolone acetonide are dysfunction of the hypothalamus – pituitary – adrenal glands, Cushing’s syndrome, slowing the growth and development of the child, the appearance of edema, increased blood pressure, hyperglycemia, glycosuria, decreased immunity. If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects not listed in the instructions, tell your doctor about it Storage conditions Store at a temperature not exceeding 25 ° C, out of the reach of children. Do not freeze. Before use, check the shelf life indicated on the package. Buy Flucinar gel 0.25 mg/g 15g №1 Price for Flucinar gel 0.25 mg/g 15g №1